EXAGGERATED INSULIN SECRETORY RESPONSE IN PATIENTS WITH INSULINOMAS TO MIDAGLIZOLE, A DRUG WITH α2‐ADRENERGIC BLOCKING ACTIVITY

Y. YAMADA*, N. KONO, T. HANAFUSA, I. MINEO, M. NAMBA, H. ITOH, H. KIYOKAWA, M. KAWACHI, T. YAMASAKI, S. TARUI

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Midaglizole is a new α2‐adrenergic blocking agent which increases insulin release from normal pancreatic islets. We studied its effect in four patients with insulinomas. In three patients oral administration of 150 mg of midaglizole caused a large increase in serum insulin and a corresponding decrease in plasma glucose. The magnitude of the response cannot exclude the possibility that midaglizole has direct beta cell stimulatory activity. Two of the three patients had operations, and their insulin responses to midaglizole became normal after removing the tumours. In contrast, midaglizole did not stimulate insulin secretion in the fourth patient. A midaglizole stimulation test might be useful in screening patients with insulinomas.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalClinical Endocrinology
Volume29
Issue number1
DOIs
StatePublished - Jul 1988

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'EXAGGERATED INSULIN SECRETORY RESPONSE IN PATIENTS WITH INSULINOMAS TO MIDAGLIZOLE, A DRUG WITH α<sub>2</sub>‐ADRENERGIC BLOCKING ACTIVITY'. Together they form a unique fingerprint.

Cite this